Shaanxi BLOOM Tech Co., Ltd. er einn af reynslumestu framleiðendum og birgjum polymyxin b dufts cas 1404-26-8 í Kína. Velkomin að heildsölu á magnsölu á hágæða polymyxin b dufti cas 1404-26-8 til sölu hér frá verksmiðju okkar. Góð þjónusta og sanngjarnt verð eru í boði.
Duft af polymyxín B, aðallega samsett úr polymyxin B sulfati, er makrósýklískt sýklalyf. Útlit þess er hvítt eða aðeins gult amorft duft, einnig lýst sem litlaust eða aðeins gult kristallað duft, næstum lyktarlaust, leysist auðveldlega upp í vatni, aðeins leysanlegt í metanóli og óleysanlegt í acetóni. Við 25 gráður C er leysanleiki þess í vatni 33,33 mg/mL. Það binst aðallega með mikilli sækni við LPS (lípópólýsakkaríðar) á vegg bakteríunnar, eyðileggur ytri himnu Gram neikvæðra baktería, eykur gegndræpi þeirra og veldur dauða baktería. Það getur einnig hlutleyst endotoxín og má nota í rannsóknum sem tengjast endotoxemíu.
It is used to treat urinary tract infections, sepsis, burn wounds, and meningitis caused by Gram negative bacteria such as Pseudomonas aeruginosa. Polymyxin B also has a certain therapeutic effect on sepsis and meningitis caused by commonly used antibiotic resistant Gram negative bacteria such as Escherichia coli and Klebsiella pneumoniae. In the field of scientific research, it can also be used for related studies such as endotoxemia.
 |
 |
is mainly reflected in its pharmaceutical application as an antibiotic.
This substance mainly targets Gram negative bacteria, including Escherichia coli, Pseudomonas aeruginosa, Escherichia coli, Klebsiella pneumoniae, Acinetobacter baumannii, as well as some Proteus and Salmonella. These bacteria often cause various infections, such as urinary tract infections, respiratory tract infections, intestinal infections, burn infections, and sepsis.
It has inhibitory or bactericidal effects and is also a peptide antibiotic against Gram negative bacteria. It binds to lipopolysaccharide (LPS) on the bacterial cell membrane with high affinity, changes the membrane structure, and causes small molecule substances to leak, thereby inhibiting the growth of Gram negative bacteria.
Treatment of severe infections: Polymyxin B is commonly used to treat severe infections caused by the aforementioned Gram negative bacteria, especially when other antibiotics are ineffective or develop resistance. It can be administered through intravenous injection, intramuscular injection, or local application, and the appropriate administration method and dosage can be selected based on the site and severity of infection.
Combination therapy: In order to improve treatment efficacy and reduce the development of drug resistance, polymyxin B is often used in combination with other antibiotics. This combination therapy can expand the antibacterial spectrum, enhance the bactericidal effect, and reduce the occurrence of adverse reactions.
Local application: In addition to systemic use, polymyxin B can also be applied locally to infected areas, such as burn wounds, eye infections, skin and soft tissue infections, etc. Local application can reduce the side effects of systemic medication, while increasing local drug concentration and enhancing bactericidal effect.
Urinary tract infections: Polymyxin B has significant antibacterial effects on various Gram negative bacteria, and is therefore commonly used to treat urinary tract infections caused by these bacteria, such as cystitis, pyelonephritis, etc.
Respiratory tract infection: Polymyxin B also has a certain therapeutic effect on respiratory tract infections caused by Gram negative bacteria, such as pneumonia, bronchitis, etc.
Intestinal infection: The intestine is one of the common sites of infection for Gram negative bacteria, and polymyxin B can be used to treat intestinal infections caused by these bacteria, such as bacterial enteritis, bacterial dysentery, etc.
Burn infection: After a burn, the wound is susceptible to invasion by Gram negative bacteria, leading to infection. Polymyxin B can be locally applied to burn wounds to prevent and treat infections.
Other infections: In addition to the indications mentioned above, polymyxin B can also be used to treat other infections caused by gram-negative bacteria, such as abdominal infections, pelvic infections, sepsis, etc.
Intravenous injection: For patients with severe infections or those who require rapid treatment, intravenous injection can be used for administration. The dosage is usually determined based on factors such as the patient's weight, site of infection, and severity.
Intramuscular injection: Intramuscular injection is another administration method of polymyxin B, suitable for patients with mild to moderate infections or those who cannot tolerate intravenous injection. The dosage also needs to be determined based on the specific condition of the patient.
Local application: For local infections such as burn infections, polymyxin B can be directly applied to the affected area to prevent and treat infections.
is a potent polypeptide antibiotic active against Gram-negative bacteria, with its primary molecular target being lipopolysaccharide (LPS) in the outer membrane of Gram-negative organisms. Its molecule carries multiple positively charged diaminobutyric acid residues, conferring strong cationic properties under physiological pH conditions. It selectively binds to the lipid A moiety of LPS via electrostatic interactions.
The structural stability of the Gram-negative outer membrane relies on divalent cations such as magnesium and calcium, which form cross-links between adjacent LPS molecules. Polymyxin B competitively displaces these cations, directly destabilizing the outer membrane and disrupting its permeability-this constitutes the critical initial step of its antibacterial activity. Owing to this targeted mode of action, it exhibits negligible antibacterial efficacy against Gram-positive bacteria lacking an LPS-containing outer membrane, granting it exceptionally high antibacterial specificity.
Following binding to the bacterial outer membrane, the hydrophobic fatty acid side chain of polymyxin B inserts into the lipid bilayer of the bacterial cytoplasmic membrane, disorganizing the ordered arrangement of membrane lipids and inducing the formation of irregular transmembrane pores. These pores penetrate both the inner and outer bacterial membranes, triggering massive leakage of intracellular nucleotides, electrolytes and low-molecular-weight metabolites, while enabling exogenous toxic substances to infiltrate the bacterial cytoplasm.
The intracellular osmotic balance of bacteria collapses completely, and core physiological processes including energy metabolism and biomolecule biosynthesis cease to function normally, ultimately resulting in bacterial lysis and death. This bactericidal mechanism is concentration-dependent: higher drug concentrations produce more severe membrane damage and faster bacterial killing, with a low propensity for the emergence of resistant mutants.
Beyond direct bactericidal activity, polymyxin B binds free LPS endotoxins to block endotoxin-mediated activation of host inflammatory signaling cascades, mitigating inflammatory storms and toxic reactions induced by Gram-negative bacterial infections.
Its cationic molecular framework tightly encapsulates the active epitopes of endotoxins and suppresses toxin recognition and downstream immune responses. While exerting anti-infective effects, it alleviates secondary tissue damage stemming from bacterial infection-this represents a key clinical advantage for treating severe infections caused by multidrug-resistant Gram-negative pathogens.
Fermentation using Bacillus strains serves as the dominant industrial and laboratory-scale manufacturing method for polymyxin B, with Bacillus polymyxa as the core production strain that inherently biosynthesizes a polymyxin B complex.
Prior to fermentation, a liquid culture medium containing glucose, corn steep liquor and inorganic salts is prepared, adjusted to a pH range of 7.0–7.5, and sterilized at high temperature before inoculation with activated seed culture. Strict temperature control at 30–32 ℃, continuous aeration and agitation are maintained throughout fermentation to sustain sufficient dissolved oxygen and a stable metabolic environment for microbial proliferation.
The full fermentation cycle lasts 3 to 5 days. During the logarithmic growth phase, the strain synthesizes large quantities of polymyxin B and secretes it extracellularly, yielding fermentation broth enriched with high concentrations of the target product. This biosynthetic process operates under mild reaction conditions and delivers high-product bioactivity, making it the primary approach for commercial mass production.
Upon fermentation completion, centrifugation and filtration are first performed to remove bacterial cell debris and medium impurities, yielding a clarified crude extract. Leveraging the cationic character of polymyxin B, ion-exchange resin is applied for adsorptive enrichment; elution generates a partially purified product solution.
Subsequent ultrafiltration and chromatographic separation eliminate contaminating heteropolypeptides, metabolic byproducts and pigments to elevate product purity.
The material is then acidified with sulfuric acid to convert it into polymyxin B sulfate, which possesses superior chemical stability. Low-temperature concentration, vacuum drying and milling are carried out sequentially to obtain the final powdered product. This purification workflow effectively eliminates side products and ensures the antibacterial potency and purity of finished goods comply with pharmaceutical standards.
Native fermented polymyxin B consists of multiple isoforms including polymyxin B1 and B2. Mild chemical modification is implemented to enhance the stability and homogeneity of the finished product by optimizing molecular spatial conformation, reducing systemic toxicity while fully retaining antibacterial activity.
. Full-process sterile and impurity-controlled handling prevents microbial contamination, securing long-term storage stability and clinical safety of the powdered formulation.
The finished powder is directly applicable for topical anti-infective therapy, antimicrobial susceptibility testing, and compounding of clinical pharmaceutical preparations.
The product, as an antibiotic, has specific development prospects in the medical field. The following is a detailed analysis of its development prospects:
With the improvement of global medical standards and the intensification of population aging trends, the demand for antibiotics continues to grow. Especially in dealing with Gram negative bacterial infections, polymyxin B, as an important class of antibiotics, has unique antibacterial mechanisms and therapeutic effects, and has therefore been widely used in clinical practice. In the future, with the increasing demand for prevention, control and treatment of infectious diseases, the market demand for polymyxin B is expected to continue to grow.
In the field of pharmaceutical research and development, innovation is an important driving force for the development of drugs. Researchers are constantly exploring new application areas and improving dosage forms for polymyxin B to enhance its efficacy and safety. For example, by changing the way drugs are administered, improving drug targeting, and reducing drug side effects, the clinical application value of polymyxin B can be further enhanced. These R&D innovations will bring it broader development prospects.
+
-
Polymyxin B is a potent antibiotic used primarily to treat serious, hard-to-treat infections caused by Gram-negative bacteria. Because of its toxicity, systemic use is usually reserved for severe hospital-acquired infections that are resistant to other safer antibiotics.
+
-
Polymyxin B ophthalmic drops (often combined with trimethoprim) are prescription antibiotics used to treat bacterial eye infections, including acute bacterial conjunctivitis (pink eye) and blepharoconjunctivitis.
maq per Qat: polymyxin b duft cas 1404-26-8, birgjar, framleiðendur, verksmiðja, heildsala, kaupa, verð, magn, til sölu